Excess Sudden Cardiac Deaths after Short-Term Clarithromycin Administration in the CLARICOR Trial: Why Is This So, and Why Are Statins Protective?
@article{Winkel2011ExcessSC, title={Excess Sudden Cardiac Deaths after Short-Term Clarithromycin Administration in the CLARICOR Trial: Why Is This So, and Why Are Statins Protective?}, author={P. Winkel and J. Hilden and J. Fischer Hansen and P. Hildebrandt and J. Kastrup and H. J. Kolmos and E. Kj{\o}ller and C. Jespersen and C. Gluud and G. Jensen}, journal={Cardiology}, year={2011}, volume={118}, pages={63 - 67} }
Objectives: To elucidate potential mechanisms for the clarithromycin-induced excess mortality observed in the CLARICOR trial during 2.6 year follow-up of patients with stable coronary artery disease. Methods: Cox analyses using out-of-hospital death as a proxy for sudden death compared to in-hospital (nonsudden) death. Result: In 100 of 189 (53%) cardiovascular (CV) deaths in which it was possible to examine the question, there was a strong association between place of death and the… Expand
Paper Mentions
Interventional Clinical Trial
A growing body of evidence links Chlamydia pneumoniae to the progression of coronary heart
disease. The purpose of this study is to determine the positive and negative effect of 14… Expand
Conditions | Cardiovascular Disease, Heart Disease |
---|---|
Intervention | Drug |
33 Citations
Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial.
- Medicine
- International journal of cardiology
- 2015
- 55
- PDF
Circulating endostatin as a risk factor for cardiovascular events in patients with stable coronary heart disease: A CLARICOR trial sub-study.
- Medicine
- Atherosclerosis
- 2019
- 3
- PDF
Pregnancy Associated Plasma Protein-A as a Cardiovascular Risk Marker in Patients with Stable Coronary Heart Disease During 10 Years Follow-Up—A CLARICOR Trial Sub-Study
- Medicine
- Journal of clinical medicine
- 2020
- 1
- PDF
Prognostic value of 12 novel cardiological biomarkers in stable coronary artery disease. A 10-year follow-up of the placebo group of the Copenhagen CLARICOR trial
- Medicine
- BMJ Open
- 2020
- PDF
Cathepsin B and S as markers for cardiovascular risk and all-cause mortality in patients with stable coronary heart disease during 10 years: a CLARICOR trial sub-study.
- Medicine
- Atherosclerosis
- 2018
- 13
- PDF
Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: The CLARICOR trial
- Medicine
- Scandinavian journal of clinical and laboratory investigation
- 2014
- 19
Predictors for major cardiovascular outcomes in stable ischaemic heart disease (PREMAC): statistical analysis plan for data originating from the CLARICOR (clarithromycin for patients with stable coronary heart disease) trial
- Medicine
- Diagnostic and Prognostic Research
- 2017
- 11
- PDF
Macrolides use and the risk of sudden cardiac death
- Medicine
- Expert review of anti-infective therapy
- 2016
- 2
References
SHOWING 1-10 OF 16 REFERENCES
Statin Treatment Prevents Increased Cardiovascular and All-Cause Mortality Associated With Clarithromycin in Patients With Stable Coronary Heart Disease
- Medicine
- Journal of cardiovascular pharmacology
- 2010
- 16
Clarithromycin for 2 Weeks for Stable Coronary Heart Disease: 6-Year Follow-Up of the CLARICOR Randomized Trial and Updated Meta-Analysis of Antibiotics for Coronary Heart Disease
- Medicine
- Cardiology
- 2008
- 57
Intervention with Clarithromycin in Patients with Stable Coronary Heart Disease
- Medicine
- Heart Drug
- 2000
- 27
Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial
- Medicine
- BMJ : British Medical Journal
- 2005
- 143
- PDF
High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease.
- Medicine
- European heart journal
- 2009
- 141
- PDF
Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome.
- Medicine
- European heart journal
- 2006
- 69
- PDF
Arrhythmic and sudden death in chronic ischemic heart disease--a review of epidemiological data.
- Medicine
- Cardiac electrophysiology review
- 2002
- 8
Antimicrobial-associated QT interval prolongation: pointes of interest.
- Medicine
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
- 2006
- 174
- PDF
Trends from 1987 to 2004 in sudden death due to coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study.
- Medicine
- American heart journal
- 2009
- 79
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II.
- Medicine
- Circulation
- 2003
- 1,104
- PDF